{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T10:54:50Z","timestamp":1740135290386,"version":"3.37.3"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Anaemia is common in haemodialysis (HD) patients and associated with significant morbidity and mortality. Intravenous (IV) iron combined with erythropoiesis-stimulating agents (ESA) is the mainstay treatment of anaemia in these patients. The comparative efficacy and risk of adverse events with IV iron preparations have been assessed in only a few trials.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>This was a retrospective observational study in 2 centres designed to compare the safety and efficacy of iron sucrose (IS-Venofer\u00ae) versus iron isomaltoside (IIM-Diafer\u00ae) in haemodialysis patients. The study included patients currently on dialysis and receiving Venofer who were switched to Diafer\u00ae and monitored for at least 12\u2009months for each iron preparation.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 190 patients were included and had a mean age of 65.8\u2009years (SD\u2009\u00b1\u200915.5). Non-inferiority was confirmed with no change in mean haemoglobin per mg of iron administered over a 12-month period.<\/jats:p>\n<jats:p>In total there were 41,295 prescriptions of iron isomaltoside and 14,685 of iron sucrose with no difference in the number of reported adverse events during the study period (7 each, none were severe).<\/jats:p>\n<jats:p>There was a statistically significant effect on Hb over time after conversion, including adjustment for multiple comparisons. There were significant improvements in ferritin over time, which remained at 6\u2009months (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). The weekly iron dose was similar after adjustment (<jats:italic>P<\/jats:italic>\u2009=\u20090.02). The EPO dose did not differ significantly after month 0 in patients switched to IIM.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>This study demonstrates the comparative safety and efficacy of iron isomaltoside versus iron sucrose, with similar dosing schedules in dialysis patients. Iron isomaltoside is non-inferior to iron sucrose in maintaining Hb in patients on regular haemodialysis\/haemodiafiltration with no difference in the number of reported adverse events.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12882-020-01866-x","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T14:51:45Z","timestamp":1591195905000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Conversion of haemodialysis patients from iron sucrose to iron isomaltoside: a real-world experience"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9694-2323","authenticated-orcid":false,"given":"Jorge A.","family":"Jesus-Silva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Archie","family":"Lamplugh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sameera","family":"Dhada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James O.","family":"Burton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Bhandari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"key":"1866_CR1","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/S0140-6736(17)32154-2","volume":"390","author":"T Vos","year":"2017","unstructured":"Vos T, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390:1211\u201359.","journal-title":"Lancet"},{"key":"1866_CR2","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group","year":"2012","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. 2012;2:279\u2013335.","journal-title":"Kidney Int Suppl"},{"key":"1866_CR3","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/nrneph.2010.139","volume":"6","author":"A Besarab","year":"2010","unstructured":"Besarab A, Coyne DW. Iron supplementation to treat anemia in patients with chronic kidney disease. Nat Rev Nephrol. 2010;6:699\u2013710.","journal-title":"Nat Rev Nephrol"},{"key":"1866_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1159\/000444335","volume":"43","author":"T Tsukamoto","year":"2016","unstructured":"Tsukamoto T, Matsubara T, Akashi Y, Kondo M, Yanagita M. Annual iron loss associated with hemodialysis. Am J Nephrol. 2016;43:32\u20138.","journal-title":"Am J Nephrol"},{"key":"1866_CR5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/ncpneph0847","volume":"4","author":"ND Vaziri","year":"2008","unstructured":"Vaziri ND. Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease? Nat Clin Pract Nephrol. 2008;4:436\u201345.","journal-title":"Nat Clin Pract Nephrol"},{"key":"1866_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12882-017-0688-1","volume":"18","author":"A Mikhail","year":"2017","unstructured":"Mikhail A, et al. Renal association clinical practice guideline on Anaemia of chronic kidney disease. BMC Nephrol. 2017;18:1\u201329.","journal-title":"BMC Nephrol"},{"key":"1866_CR7","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/nrneph.2013.21","volume":"9","author":"WH H\u00f6rl","year":"2013","unstructured":"H\u00f6rl WH. Anaemia management and mortality risk in chronic kidney disease. Nat Rev Nephrol. 2013;9:291\u2013301.","journal-title":"Nat Rev Nephrol"},{"key":"1866_CR8","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1093\/ndt\/gfu104","volume":"30","author":"AE Gaweda","year":"2015","unstructured":"Gaweda AE, et al. Iron dosing in kidney disease: inconsistency of evidence and clinical practice. Nephrol Dial Transplant. 2015;30:187\u201396.","journal-title":"Nephrol Dial Transplant"},{"key":"1866_CR9","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1056\/NEJMoa1810742","volume":"380","author":"IC Macdougall","year":"2019","unstructured":"Macdougall IC, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med. 2019;380:447\u201358.","journal-title":"N Engl J Med"},{"key":"1866_CR10","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1080\/08860220802134631","volume":"30","author":"G Anirban","year":"2008","unstructured":"Anirban G, Kohli HS, Jha V, Gupta KL, Sakhuja V. The comparative safety of various intravenous iron preparations in chronic kidney disease patients. Ren Fail. 2008;30:629\u201338.","journal-title":"Ren Fail"},{"key":"1866_CR11","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/ajh.23712","volume":"89","author":"D Hetzel","year":"2014","unstructured":"Hetzel D, et al. A phase III, randomized, open-label trial of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with a history of unsatisfactory oral iron therapy. Am J Hematol. 2014;89:646\u201350.","journal-title":"Am J Hematol"},{"key":"1866_CR12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1093\/ndt\/16.6.1239","volume":"16","author":"M Kosch","year":"2001","unstructured":"Kosch M, et al. A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer\u00ae) vs iron gluconate (Ferrlecit\u00ae) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant. 2001;16:1239\u201344.","journal-title":"Nephrol Dial Transplant"},{"key":"1866_CR13","doi-asserted-by":"publisher","first-page":"705","DOI":"10.2215\/CJN.05320513","volume":"9","author":"IC Macdougall","year":"2014","unstructured":"Macdougall IC, et al. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD. Clin J Am Soc Nephrol. 2014;9:705\u201312.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1866_CR14","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1080\/08860220701278208","volume":"29","author":"T Sav","year":"2007","unstructured":"Sav T, et al. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran? Ren Fail. 2007;29:423\u20136.","journal-title":"Ren Fail"},{"key":"1866_CR15","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1159\/000083766","volume":"99","author":"H Sheashaa","year":"2005","unstructured":"Sheashaa H, et al. Parenteral iron therapy in treatment of anemia in end-stage renal disease patients: a comparative study between iron saccharate and gluconate. Nephron Clin Pract. 2005;99:97\u2013102.","journal-title":"Nephron Clin Pract"},{"key":"1866_CR16","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1093\/ndt\/gfv305","volume":"30","author":"M Airy","year":"2015","unstructured":"Airy M, et al. Comparative outcomes of predominant facility-level use of ferumoxytol versus other intravenous iron formulations in incident hemodialysis patients. Nephrol Dial Transplant. 2015;30:2068\u201375.","journal-title":"Nephrol Dial Transplant"},{"key":"1866_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1778-428X.2007.00050.x","volume":"9","author":"KA Moniem","year":"2007","unstructured":"Moniem KA, Bhandari S. Tolerability and efficacy of parenteral iron therapy in hemodialysis patients, a comparison of preparations. Transfus Altern Transfus Med. 2007;9:37\u201342.","journal-title":"Transfus Altern Transfus Med"},{"key":"1866_CR18","doi-asserted-by":"publisher","first-page":"3262","DOI":"10.1093\/ndt\/gfr024","volume":"26","author":"J Rottembourg","year":"2011","unstructured":"Rottembourg J, Kadri A, Leonard E, Dansaert A, Lafuma A. Do two intravenous iron sucrose preparations have the same efficacy? Nephrol Dial Transplant. 2011;26:3262\u20137.","journal-title":"Nephrol Dial Transplant"},{"key":"1866_CR19","doi-asserted-by":"publisher","first-page":"S83","DOI":"10.1111\/hdi.12560","volume":"21","author":"M Auerbach","year":"2017","unstructured":"Auerbach M, Macdougall I. The available intravenous iron formulations: history, efficacy, and toxicology. Hemodial Int. 2017;21:S83\u201392.","journal-title":"Hemodial Int"},{"key":"1866_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ph11030082","volume":"11","author":"S Bhandari","year":"2018","unstructured":"Bhandari S, Pereira DIA, Chappell HF, Drakesmith H. Intravenous irons: from basic science to clinical practice. Pharmaceuticals. 2018;11:1\u201320.","journal-title":"Pharmaceuticals"},{"key":"1866_CR21","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1001\/jama.2015.15572","volume":"314","author":"C Wang","year":"2015","unstructured":"Wang C, et al. Comparative risk of anaphylactic reactions associated with intravenous iron products. JAMA - J Am Med Assoc. 2015;314:2062\u20138.","journal-title":"JAMA - J Am Med Assoc"},{"key":"1866_CR22","volume-title":"Chronic kidney disease: managing anaemia","author":"NICE","year":"2015","unstructured":"NICE. Chronic kidney disease: managing anaemiaISBN 978\u20131\u20134731-1149-3; 2015."},{"key":"1866_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1097\/MNH.0000000000000263","volume":"25","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S. Safety of intravenous iron use in chronic kidney disease. Curr Opin Nephrol Hypertens. 2016;25:529\u201335.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"1866_CR24","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S89704","volume":"9","author":"PA Kalra","year":"2016","unstructured":"Kalra PA, Bhandari S. Efficacy and safety of iron isomaltoside (Monofer\u00ae) in the management of patients with iron deficiency anemia. Int J Nephrol Renovasc Dis. 2016;9:53\u201364.","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"1866_CR25","first-page":"49","volume":"72","author":"A Blazevic","year":"2014","unstructured":"Blazevic A, Hunze J, Boots JMM. Severe hypophosphataemia after intravenous iron administration. Neth J Med. 2014;72:49\u201353.","journal-title":"Neth J Med"},{"key":"1866_CR26","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1210\/jc.2008-2396","volume":"94","author":"BJ Schouten","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009;94:2332\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"1866_CR27","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/jbmr.1923","volume":"28","author":"M Wolf","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013;28:1793\u2013803.","journal-title":"J Bone Miner Res"},{"key":"1866_CR28","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1001\/archinte.1984.00350180105016","volume":"144","author":"LE Klein","year":"1984","unstructured":"Klein LE. Medication problems among outpatients a study with emphasis on the elderly. Arch Intern Med. 1984;144:1185.","journal-title":"Arch Intern Med"},{"key":"1866_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell L, Shakir SAW. Under-reporting of adverse drug reactions. Drug Saf. 2006;29:385\u201396.","journal-title":"Drug Saf"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-020-01866-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-020-01866-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,3]],"date-time":"2021-06-03T02:43:29Z","timestamp":1622688209000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-020-01866-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1866"],"URL":"https:\/\/doi.org\/10.1186\/s12882-020-01866-x","relation":{},"ISSN":["1471-2369"],"issn-type":[{"type":"electronic","value":"1471-2369"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"8 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was part of service improvement in the implementation and assessment of a change in therapy and was registered (Project Number 10351) with the University Hospitals of Leicester NHS Trust Clinical Audit, Standards and Effectiveness (CASE) Team who provided permission and support for the use of anonymised patient records to assess the impact of the intervention. This study was also given a favourable opinion from the Hull University Teaching Hospitals NHS Trust Research and Development Committee who provided approval for the use of anonymised patient data for the potential benefit of service and patient care. All the principles of the declaration of Helsinki and the ICH and good governance were followed and data anonymity was maintained throughout.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors read and approved the final manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The results presented in this paper have not been published previously in whole or part, except in abstract format. Dr. Jorge Jesus-Silva has received funding from Pharmacosmos to attend and present a poster in abstract at the American Society of Nephrology conference. Professor James Burton has received honoraria for lectures, attended expert opinion committees and received sponsorship to attend congresses from Pharmacosmos, Vifor Pharma, NAPP and Bristol-Myers Squibb. Professor Sunil Bhandari has received honoraria for lectures, attended expert opinion committees, and received educational funds to attend the European Renal Association-European Dialysis and Transplant Association from Pharmacosmos and Vifor Pharma. Mr. Archie Lamplugh, Sameera Dhada and Beverly Pearce have no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}